{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:38:55Z","timestamp":1793619535228,"version":"4.5.0"},"reference-count":56,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna","doi-asserted-by":"crossref","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Virol"],"published-print":{"date-parts":[[2024,4,16]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              mRNA-1647 is an investigational mRNA-based vaccine against cytomegalovirus (CMV) that contains sequences encoding the CMV proteins glycoprotein B and pentamer. Humoral and cellular immune responses were evaluated in blood samples collected from healthy CMV-seropositive and CMV-seronegative adults who participated in a phase 1 trial of a three-dose series of mRNA-1647 (NCT03382405). Neutralizing antibody (nAb) titers against fibroblast and epithelial cell infection in sera from CMV-seronegative mRNA-1647 recipients were higher than those in sera from control CMV-seropositive samples and remained elevated up to 12 months after dose 3. nAb responses elicited by mRNA-1647 were comparable across 14 human CMV (HCMV) strains. Frequencies of antigen-specific memory B cells increased in CMV-seropositive and CMV-seronegative participants after each mRNA-1647 dose and remained elevated for up to 6 months after dose 3. mRNA-1647 elicited robust increases in frequencies and polyfunctionality of CD4\n              <jats:sup>+<\/jats:sup>\n              T helper type 1 and effector CD8\n              <jats:sup>+<\/jats:sup>\n              T cells in samples from CMV-seronegative and CMV-seropositive participants after stimulation with HCMV-specific peptides. The administration of three doses of mRNA-1647 to healthy adults elicited high nAb titers with wide-breadth, long-lasting memory B cells, and strong polyfunctional T-cell responses. These findings support further clinical development of the mRNA-1647 vaccine against CMV.\n            <\/jats:p>\n            <jats:sec>\n              <jats:title>IMPORTANCE<\/jats:title>\n              <jats:p>Cytomegalovirus (CMV), a common virus that can infect people of all ages, may lead to serious health problems in unborn babies and those with a weakened immune system. Currently, there is no approved vaccine available to prevent CMV infection; however, the investigational messenger RNA (mRNA)\u2013based CMV vaccine, mRNA-1647, is undergoing evaluation in clinical trials. The current analysis examined samples from a phase 1 trial of mRNA-1647 in healthy adults to better understand how the immune system reacts to vaccination. Three doses of mRNA-1647 produced a long-lasting immune response, thus supporting further investigation of the vaccine in the prevention of CMV infection.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n              <jats:title>CLINICAL TRIALS<\/jats:title>\n              <jats:p>\n                Registered at ClinicalTrials.gov (\n                <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03382405\" xlink:type=\"simple\">NCT03382405<\/jats:ext-link>\n                ).\n              <\/jats:p>\n            <\/jats:sec>\n          <\/jats:sec>","DOI":"10.1128\/jvi.01603-23","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T12:50:26Z","timestamp":1711371026000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":27,"title":["Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults"],"prefix":"10.1128","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6679-2803","authenticated-orcid":false,"given":"Kai","family":"Wu","sequence":"first","affiliation":[{"name":"Infectious Disease Research, Moderna, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan Jacob","family":"Hou","sequence":"additional","affiliation":[{"name":"Infectious Disease Research, Moderna, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Makrinos","sequence":"additional","affiliation":[{"name":"Infectious Disease Research, Moderna, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runxia","family":"Liu","sequence":"additional","affiliation":[{"name":"Infectious Disease Research, Moderna, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Zhu","sequence":"additional","affiliation":[{"name":"Infectious Disease Research, Moderna, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Koch","sequence":"additional","affiliation":[{"name":"Infectious Disease Research, Moderna, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Han","family":"Yu","sequence":"additional","affiliation":[{"name":"Infectious Disease Research, Moderna, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamuna D.","family":"Paila","sequence":"additional","affiliation":[{"name":"Infectious Disease Development, Moderna, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumana","family":"Chandramouli","sequence":"additional","affiliation":[{"name":"Infectious Disease Research, Moderna, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Panther","sequence":"additional","affiliation":[{"name":"Infectious Disease Development, Moderna, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Henry","sequence":"additional","affiliation":[{"name":"Infectious Disease Research, Moderna, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"DiPiazza","sequence":"additional","affiliation":[{"name":"Infectious Disease Research, Moderna, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5508-3809","authenticated-orcid":false,"given":"Andrea","family":"Carfi","sequence":"additional","affiliation":[{"name":"Infectious Disease Research, Moderna, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2034"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-021-00582-z"},{"key":"e_1_3_5_4_2","unstructured":"Centers for Disease Control and Prevention. 2020. Clinical overview. Available from: https:\/\/www.cdc.gov\/cmv\/clinical\/overview.html. Accessed 18 July 2023."},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.10.1.86"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.089"},{"key":"e_1_3_5_7_2","unstructured":"Centers for Disease Control and Prevention. 2022. Babies born with congenital CMV. Available from: https:\/\/www.cdc.gov\/cmv\/congenital-infection.html. Accessed 18 July 2023."},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2222583"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.01.029"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9071(199708)52:4%3C451::AID-JMV18%3E3.0.CO;2-J"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.18.10023-10033.2004"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01251-08"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.16.10330-10338.2005"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509201102"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj9853"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz428"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1800177115"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2020.04.003"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059863"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines5040039"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-77349-8_4"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.000882"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1806305115"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature07209"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2016.82"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006281"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.06.028"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1814850116"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002905"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aan1457"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1424818112"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005230"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01650-16"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.036"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.83523-0"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01809-09"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.07.092"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00747-19"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz447"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054417"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb3611"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167768"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI156827"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410x(91)90187-b"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9176"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00467-12"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7030070"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01787"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13019"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0244-2"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02458"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2022.101726"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050882"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.5.2869-2879.2005"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.05.022"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0829"}],"container-title":["Journal of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jvi.01603-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jvi.01603-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T15:57:37Z","timestamp":1713283057000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jvi.01603-23"}},"subtitle":[],"editor":[{"given":"Felicia","family":"Goodrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,16]]}},"alternative-id":["10.1128\/jvi.01603-23"],"URL":"https:\/\/doi.org\/10.1128\/jvi.01603-23","relation":{},"ISSN":["0022-538X","1098-5514"],"issn-type":[{"value":"0022-538X","type":"print"},{"value":"1098-5514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]},"assertion":[{"value":"2023-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01603-23"}}